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ABSTRACT  
Objective: The present research work was aimed to observe the effect of Metformin hydrochloride (MET) on non-enzymatic glucosylation of 
recombinant human serum albumin (rHSA). 
Methods: Albumin was incubated at 37 ° in 10 mM phosphate buffer (pH 7.4) using 0.2% sodium azide for 7 d with different concentrations of D-
(+)-glucose and MET. Incorporation of D-(+)-glucose (5-12 mM) into rHSA was calculated in the presence of metformin hydrochloride (1-5 µg/ml) 
following extensive dialysis of the incubation mixture. The binding experiments were exercised at respective plasma concentration of rHSA, D-(+)-
glucose and MET in corresponding to that of diabetic and non-diabetic population. Glycosylation of rHSA was quantified using 2-thiobarbituric acid 
(2-TBA). Whereas, metformin hydrochloride was quantified using a validated LC-MS/MS method with negative ion electrospray ionization using 
multiple reactions monitoring (MRM) mode. MET was eluted isocratically on X-Bridge BEH Phenyl column with a mobile phase consisting of 
mixture of water (containing 50 mM ammonium acetate) and acetonitrile in a ratio of 70:30.  
Results: The weighted (1/X2
Conclusion: All the described parameters were in accordance to the FDA Guideline (inside 85-115% for the accuracy and less than 15% for the 
precision), thus it can be concluded that the bioanalytical method is were fully validated as per USFDA guideline. These experiments showed the 
affinity of MET toward the rHSA proved to be higher than its affinity toward the glucose. 
) calibration curve from 20 to 10, 000 ng/ml was employed for the calculation of MET in sample with line equation of 
Y= 0.0020584x+0.0037475. The binding pattern of MET to rHSA, was specific and pH dependent, possibly due to a change in ionization state of MET 
and change in conformation of rHSA during the binding process.  
Keywords: Recombinant human serum albumin (rHSA), Metformin hydrochloride, glycosylation of albumin, Protein binding, LC-MS/MS  
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INTRODUCTION  
Albumin is known to have a set of multitude functions viz. binding 
and transport capacities, oncotic pressure regulation and 
antioxidant properties [1]. Non-enzymatic glycation is one of the 
primary modification factors that contribute to various alterations in 
functions of serum albumin particularly in diabetes [2]. Erythrocyte 
protein [3], lipoprotein [4], nerve proteins [5], lens protein [6] and 
plasma proteins [7] are glycosylated more in diabetic patients as 
compare to non-diabetic subjects and play a key role in progression 
of chronic diabetic complications [8]. Binding of drugs have been 
impaired due to glycosylation of albumin in both in vitro and in vivo 
conditions [9]. Oral antidiabetic sulfonylurea, gliclazide has shown 
increase in binding with glycosylated albumin [10]. Indurthi et al. 
(2014) have observed that albumin binding sites were altered due to 
various glycosylation reagents in a reagent specific manner [11]. 
Thus the binding of diclofenac was altered with modified 
glycosylated serum albumin.  
Inorganic [12] and organic polyamine cations [13] has shown 
binding with HSA in a pH-specific manner. The authors have 
observed that the polyamine cations induce conformational changes 
with a reduction of α-helicles and increase in β-structure of HSA.  
Metformin HCl (MET; fig. 1), is a strongly basic compound with pKa 
about 11, present in cationic form under physiological conditions, 
which is seem to be essential for its mechanism. MET is known to 
repair antioxidant property of serum albumin [14]. MET inhibit the 
formation of early, intermediate and advanced glycation end products 
[15]. The interaction of MET with levofloxacin lowered the affinity and 
decreased the percentage of binding of MET in the mixture to bovine 
serum albumin (BSA) leads to increase in free MET concentration in 
plasma [16]. One of the possible mechanism of inhibition of formation 
of advanced glycation end products is reaction of MET with dicarbonyl 
compounds [17]. MET induce conformational change in human serum 
albumin and glycosylated albumin. The α-content of HSA was 
decreased MET concentration dependent [18]. 
  
  
Fig. 1: Chemical structures of (a) Metformin and (b) Ranitidine (IS) 
 
The present study was conducted to assess the effect of MET on non-
enzymatic glycosylation of rHSA in in vitro condition. Equilibrium 
dialysis and ultrafiltration techniques were employed to observe protein 
binding for glycosylated and non-glycosylated albumin. MET was 
quantified using validated liquid chromatography coupled to tandem 
mass spectrometric method. 
MATERIALS AND METHODS 
Chemical and reagents  
Qualified standard of ranitidine hydrochloride (>99.8 %) was gifted 
by torrent research centre (TRC Ahmadabad, India). The standards 
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of metformin hydrochloride, recombinant human serum albumin 
(rHSA) and glucosylated human serum albumin (Gly-HSA) were 
purchased from sigma aldrich (Bangalore, India) and used as 
supplied. Analytical/HPLC grade chemicals and solvents used were 
purchased from ranbaxy fine chemicals limited (Delhi, India). Unless 
otherwise specified, all solutions were filtered using 0.22 µm Ultipor®
Instrumentation and chromatographic conditions 
 
Nylon-66 membrane filter (Pall Life Sciences, USA) prior to use. 
The liquid chromatography (LC) system coupled with mass 
spectrometry (MS/MS), used for quantitation of MET, was consisting 
of solvent delivery (LC 10ADVP), controller (LC10ADVP), 
autosampler (SIL HTC) and column oven (CTO10ASVP) from 
Shimadzu (Kyoto, Japan). The 10 µl aliquots of the processed 
samples were injected on Xbridge BEH Phenyl (75 x 4.6 mm, 2.5 µm 
particle size and 130Å pore size) column. The isocratic mobile phase 
consisting of a mixture of water (containing 50 mM ammonium 
acetate) and acetonitrile (ACN) in a ratio of 70:30 was delivered at 
0.5 ml/min into the mass spectrometer’s electrospray ionization 
chamber. The total run time for analysis was 5.0 minute. Ranitidine 
hydrochloride (fig. 1b) was used as internal standard (IS) for 
quantitation method of MET. Quantitation was achieved by MS/MS 
detection in positive ion modes for both MET and ranitidine (IS) 
using a triple quadruple mass spectrometer (API 2000) made by AB 
Sciex Instruments (Toronto, Canada). The split ratio, cone voltage 
and collision energy were 1:7, 20V and 20eV, respectively. Detection 
of the ions was performed in the multiple reaction monitoring 
(MRM) mode using the transition pairs of MET at the m/z 130.1 
precursor ion to the m/z 70.9 and m/z 315.02 precursor ion to the 
m/z 176.15 product ion for IS. The analytical data was processed by 
Analyst software (version 1.4.1). All the chromatograms into the 
same batch were processed automatically by the software using the 
same processing parameters such as integration type, smooth, peak-
to-peak amplitude and peak detection.  
The validation parameters viz. specificity, calibration curve, 
precision and accuracy and stability studies were exercised as per 
the USFDA’s bioanalytical validation guideline [19] for 
determination of MET spiked to rHSA. The calibration curve was 
performed from 20 to 10, 000 ng/ml of MET. Three quality control 
(QC) batches representing concentration 100, 1000 and 8000 ng ml-
1
Extraction studies for MET  
of MET for lower QC (LQC), middle QC (MQC) and higher QC (HQC), 
respectively, were employed for accessing accuracy and precision 
(PandA). The stability of the MET in spiked sample as well as in 
analytical solution was observed for 90 d.  
Protein precipitation technique was employed for extraction of MET 
form rHSA [20]. For spiking purposes a laboratory mixture, 
containing rHSA (47.5 mg/ml) and 5 mM of D-(+)–glucose and 0.05 
parts of internal standard in water, was prepared and used as 
Plasma blank. The protein precipitation was carried out for a plasma 
blend containing 1 part of plasma blank and 0.1 part of drug. About 
20 µl of Diluted standard solution containing MET (10 µg/ml) was 
added to 200 µl of plasma blank in a 1.5 ml capacity micro-
centrifuge tube. The blend was subjected to vortex for about 3 min. The 
mixture was allowed to stabilize for two minutes then 770 µl of ACN was 
added and the blend was subjected to vortex for two minute. The 
mixture was subjected to vortex for 10 min followed by centrifugation 
for 10 min at 15,000 rpm. The mixture was allowed to stabilize for two 
minutes then 100 µl of supernatant washed using dichloromethane and 
dried. The extracts were reconstituted with a fixed volume of water and 
an aliquot of that was analysed by LC-MS/MS. 
Influence of MET on glycosylation of rHSA 
The laboratory mixture for rHSA (Fraction V; 47.5 mg/ml) solution 
was prepared in 10 mM phosphate buffer (pH 7.4) with0.2% (w/v) 
sodium azide and D-(+)-glucose corresponding to plasma 
concentrations ranging from 5-12 mM. Following the addition of D-
(+)-glucose, MET was added to its plasma concentration range from 
1-5 µg/ml. The laboratory mixture was incubated for upto7 d in 
capped, sterile vials at 37 ° and 20 RPM in envirogenie®
2-Thiobarbituric acid test for glucosylated albumin 
 metabolic 
shaker. The pH of the reaction solutions was varied from 5.0-11.0 
and difference in glycosylation was observed at 10 mM glucose 
concentration correspondence to plasma concentration of MET (5 
µg/ml). At the end of each incubation period, 1-ml samples were 
removed and dialyzed against several 1000-fold volumes of distilled 
water for 24 h at 4 °. The remainder was lyophilized and stored at-
20 °. A portion of the dialysate was monitored for the presence of 
free glucose by the glucose oxidase method. The remainder was 
lyophilized and stored at-20 °. Incubated samples were compared to 
control samples which were prepared and incubated for same time 
period by dissolving identical quantities of albumin incubated with 
glucose in phosphate buffer and dialyzing against distilled water for 
24hr [21]. 
The assay of glucosylated albumin (Gly-HSA) was performed with 
little modification as procedure described in literature [7]. About 5 
mg lyophilized samples of glucosylation process end product of 
rHSA were placed in 15-ml culture tubes and dissolved in distilled 
water (2 ml). After the addition of 1.0 N oxalic acid (1.0 ml), the 
tubes were gently shaken, capped, and placed in a heating block at 
98 ° for 6 hr. The tubes were subsequently cooled and cold 10% 
trichloroacetic acid (0.5 ml) was added to precipitate the protein. 
The contents were then centrifuged at 9000 ×g for 10 min. An 
aliquot (2 ml) of the supernate was removed and added to a solution 
of 0.05 M aqueous 2-thiobarbituric acid (1.0 ml). After mixing and an 
incubation period of 20 min at 37 °, the absorbance of each sample 
was measured at 442 nm using an UV-Visible spectrophotometer 
(Shimadzu 1800, Kyoto Japan). 
Isolation of unbound MET and determination of its 
concentration in rHSA and Gly-HSA solutions 
Binding of MET was observed for non-glycosylated and 10-15 % 
glycosylated rHSA. The results of protein binding were compared for 
equilibrium dialysis and ultrafiltration techniques. A mass balance 
approach was performed for assaying MET in dialyzed as well as in 
the undialyzed samples. Amicon® ultrafiltration tubes were utilized 
to perform protein binding experiment. MET present in dialysate or 
in filtrate, was quantified using the validated LC-MS/MS method 
without any extraction step. The dialysate was diluted and filtered 
through 0.45 µm Dispo®
RESULTS  
 syringe nylon filter for every step. MET and 
the IS were extracted from rHSA by protein precipitation extraction 
method as mentioned in Section 2.3. At the end, the mass balance 
studies were executed to estimate the protein binding of MET. 
Liquid chromatographic mass-spectrometric system 
MET was eluted isocratically on X-Bridge BEH Phenyl (75 x 4.6 mm, 
2.5 µm particle size and 130Å pore size) column with a mobile phase 
consisting of mixture of water (containing 50 mM ammonium 
acetate) and acetonitrile in a ratio of 70:30. Typical chromatograms 
of the MRM transition for MET and IS are shown in fig. 2.  
The method had fulfilled the requirement of analysis with the use of 
MRM transitions130.1>70.9 and 315.02>176.15 for MET and IS, 
respectively as shown in fig. 3. 
Validation of LC-MS/MS method  
All the described parameters were in accordance to the FDA 
guideline (inside 85-115% for the accuracy and less than 15% for 
the precision), it can be concluded that the bioanalytical method was 
fully validated as per USFDA guideline and sufficient to quantify the 
MET in rHSA. Results of bio-analytical method validation for MET in 
rHSA are summarized in table 2.  
Inhibition of glucose binding to rHSA 
Glycosylated albumin was quantified using method as described in 
literature. It was including formation of 5-(hydroxy-methyl)-2-
furaldehyde, as a result of ketamine covalent linkage between 
glucose and rHSA followed by reduction with oxalic acid, which 
shown a characteristic coloured adduct with 2-thiobarbituric acid 
(2-TBA). Increase in free glucose concentration was observed with 
corresponding increase in MET concentration or vice versa.  
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Incubation of MET with rHSA at physiological pH and temperature 
was resulted in the displacement of glucose binding sites of rHSA. 
The incorporation of glucose to rHSA was decreased linearly with 
increase in plasma concentration of MET.  
The binding pattern is glucose was found though specific and linear. 
About 5-10% inhibition was observed at higher MET concentration. 
The result of influence of MET on non-enzymatic glucosylation of 
rHSA is shown in fig. 4. 
 
 




Fig. 3: Mass spectra of MET precursor ion (a), product ion (b), mass spectra of Ranitidine precursor ion (c) and product ion (d) 
Talele et al. 




Fig. 4: Influence of MET on non-enzymatic glucosylation of rHSA 
 
The degree of in vitro non-enzymatic glucosylation process of rHSA 
was depended mainly on the pH of buffer. At pH 6.5~7.5, the rHSA is 
assumed to be a weak cation exchanger which exhibited negative 
charge, uniformaly distributed at the surface. The reaction between 
rHSA and D-(+)-glucose most likely occurs by means of a 
nucleophilic interaction of an unprotonated amino group of rHSA 
toward the glucose molecule. At physiological pH, few of the primary 
groups exist of rHSA in the unprotonated state. At physiological pH 
MET exist in the ionized form, which is the active form of the drug. 
Therefore, MET may be preferred to make interaction with rHSA as 
compare to glucose and this situation may account for the relatively 
slow rate of the glucosylation reaction in the presence of MET. At 
physiological pH and temperature, incorporation of MET to rHSA 
was although specific and but biphasic and not similar to binding 
pattern of glucose. The dissimilarity of binding pattern of MET as 
compare to glucose at higher pH value possibly due to its varying 
degree of ionization. However, at every glucose concentration 
employed, MET incorporation into rHSA was significantly greater 
than that incorporated by rHSA bound with glucose particularly at 
pH value less than 9.0. Here we can predict that within the protein 
molecule with free-COO-groups preferentially to bonds with the 
quaternary form of MET (-NH+). The affinity of rHSA for MET would 
be limited since the-COO-
The rate of MET incorporation into rHSA was independent to the 
incubation period. Whereas, incorporation of glucose to rHSA was 
concentration depended. In cases of glucose binding, the incubation 
of glucose to rHSA was incorporation was linear and time 
dependent, whereas, glycosylation of rHSA was affected by MET in a 
concentration and time independent manner as shown in fig. 5. 
groups are “blocked” by internal-OH bonds. 
 
 
Fig. 5: Effect of incubation period on non-enzymatic glucosylation of rHSA in the presence of MET 
 
We had observed that MET inhibits non-enzymatic glcosylation of 
rHSA. Protein binding MET to albumin was low and concentration 
independent as shown in fig. 6. Binding of MET to glycosylated HSA 
has followed the same pattern as that of non-glycosyalted HSA with 
significantly lower in binding of MET to glycated albumin. 
DISCUSSION  
Optimization of the chromatographic system 
MET is a weak base with high pKa value (BH+
Several columns were tested for metformin retention, including the 
Atlantis HILIC, Water phenyl, YMC Pack Pro–Cyno and conventional 
, 11.41) [22] and the 
drug had shown very short retention on reversed phase column. 
Therefore, Reversed phase HPLC method was not the first choice to 
estimate the MET in in vitro solutions. Various analytical techniques 
viz. ion-pair reversed phase LC, normal phase LC, HILIC and liquid 
chromatography coupled with mass spectrometry have been 
employed to solve this problem. Among these techniques, ion pair-
reversed phase HPLC is the most commonly used method for 
metformin analysis with “controllable” retention in reversed phase 
sorbent. Initially, a cationic ion pair HPLC method was developed for 
estimation of MET spiked in rHSA. Though the method was capable 
in quantifying the MET but in complex matrices, an additional 
degree of certainty is required to confirm the presence of metformin, 
which was achieved by the cationic ion-pair method. MET eluting 
close to the solvent front, resulted in a difficult separation and poor 
resolution of metformin from co-eluting matrix components 
especially from plasma protein. Therefore, MS was decided for 
detection coupled to LC as method of choice.  
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reversed phase columns (i.e. C8 and C18). Both the C8 and C18 
results showed poor retention due to hydrophilic and ionic 
character of MET in pH range of essential in chromatography 
working. Less non polar or more polar stationary phases like–Phenyl 
was better alternative technique to reversed-phase chromatography 
for strongly hydrophilic, polar and ionic compounds. 
The selected stationary phase was providing complementary 
selectivity to non-polar sorbent of reversed phase LC, especially for 
polar compounds. The eluent was an equal volume combination of 
aqueous buffer that contain ammonium acetate and ACN as organic 
phase. The selectivity of the selected stationary phase for MET was 
tuned by varying the amount of organic phase in combination with 
the ionic strength and the pH of buffer phase. A series of aqueous 
mobile phases containing different pH values, different 
concentration buffer solutions and different volume fractions of 
organic modifier were tested. The optimized LC conditions were 
achieved with a mobile phase of 10 mM aqueous ammonium acetate 
and ACN (70:30, v/v). Typical chromatograms of the MRM transition 
for MET and IS are shown in fig. 2. For MS detection, optimization 
was performed for two types of interfaces in both the negative and 
the positive ion mode, and these were subsequently compared for 
sensitivity of the response. Negative ion mode produced better 
results than positive ion mode.  
Validation of LC-MS/MS method  
The matrix effect for the accurate estimation of MET was observed 
by spiking MET to rHSA. The MS response for mean matrix effect 
(n=6) was less than 5% as compare to that of MET LLOQ (i.e. 20 
ng/ml). Consequently, we prepared the calibration standards by 
adding metformin working standard solution into blank matrices. 
The response function of the MS instrument is corrected by applying 
weighing to the calibration curve for back calculation of lower 
concentration samples. The “1/X” weighted calibration curve was 
providing least error in recovery value at LLOQ level (table 1). 
  





Unweighted linearity curve 1/X weighted linearity curve 
m c Sy. x r %MRE2 m  LLOQ C SE %MREc LLOQ 










m and c are slope and y-intercept, respectively, for line equation of y=mx+c. SEc is standard error of Y-intercept. And %MRELLOQ 
 
is %Mean relative 
error at LLOQ level 
Since all the described parameters were in accordance to the FDA 
Guideline (inside 85-115% for the accuracy and less than 15% for 
the precision), it can be concluded that the bioanalytical method is 
were fully validated as per USFDA guideline and sufficient to 
quantify the MET in rHSA. Results of bio-analytical method 
validation for MET in rHSA are summarized in table 2. 
  
Table 2: The summary of LC-MS/MS Bioanalytical method validation for MET spiked in rHSA 
Parameter  Procedure  Results  
Specificity  Matrix effect due to fatty acid free rHSA and human plasma, 
Dilution integrity and injection carry over test for six injection  
No interference was observed at retention 
time of MET and IS 
Calibration curve In the range of 20 (LLOQ) to 10, 000 ng ml-1 Weighing of 1/Xand “Goodness of fit”  2
Precision and 
Accuracy 
 with line equation of Y= 
0.0020584x+0.0037475 
For each QC level, coefficient of variation (% CV for n=6 samples) not 
exceeding 15% on 
 
Intra Batch (Same 
day)  
Same day and on  
 
Precision= 4.64 Accuracy = 97.8 
Inter Batch (Different 
day) 
Different days Precision= 5.13 Accuracy = 98.9 
Recovery studies  Evaluated by calculating the mean of the concentration of each extracted QC 
sample set and dividing by the mean of the Unextracted sample set. 
72.1±1.15 
Stability*   
Post-processing 
stability 
Six aliquots of QC samples at 8-15˚ for 72 h 2.95 
Freeze-and Thaw 
Stability Tests 





Six aliquots of QC samples at 8-15˚ for 90 d 6.96 
* Stability experiments were performed at two QC level in triplicate  
 
Inhibition of glucose binding to rHSA 
Formation of 5-(hydroxy-methyl)-2-furaldehyde, was prepared 
through ketamine covalent linkage between glucose and rHSA 
followed by reduction with oxalic acid, had shown a characteristic 
coloured adduct with 2-thiobarbituric acid (2-TBA). Increase in free 
glucose concentration was observed with corresponding increase in 
MET concentration or vice versa.  
Incubation of MET with rHSA at physiological pH and temperature 
was resulted in the displacement of glucose binding sites of rHSA. 
The incorporation of glucose to rHSA was decreased linearly with 
increase in plasma concentration of MET. The binding pattern is 
glucose was found though specific and linear. About 5-10% 
inhibition was observed at higher MET concentration. The result of 
influence of MET on non-enzymatic glucosylation of rHSA is shown 
in fig. 4. The degree of in vitro non-enzymatic glucosylation process 
of rHSA was depended mainly on the pH of buffer. At pH 6.5~7.5, the 
rHSA is assumed to be a weak cation exchanger which exhibited 
negative charge, uniformaly distributed at the surface. The reaction 
between rHSA and D-(+)-glucose most likely occurs by means of a 
nucleophilic interaction of an unprotonated amino group of rHSA 
toward the glucose molecule. At physiological pH, few of the primary 
groups exist of rHSA in the unprotonated state. At physiological pH 
MET exist in the ionized form, which is the active form of the drug. 
Therefore, MET may be preferred to make interaction with rHSA as 
compare to glucose and this situation may account for the relatively 
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slow rate of the glucosylation reaction in the presence of MET. At 
physiological pH and temperature, incorporation of MET to rHSA 
was although specific and but biphasic and not similar to binding 
pattern of glucose. The dissimilarity of binding pattern of MET as 
compare to glucose at higher pH value possibly due to its varying 
degree of ionization. However, at every glucose concentration 
employed, MET incorporation into rHSA was significantly 
greater than that incorporated by rHSA bound with glucose 
particularly at pH value less than 9.0. Here we can predict that 
within the protein molecule with free-COO-groups preferentially 
to bonds with the quaternary form of MET (-NH+). The affinity of 
rHSA for MET would be limited since the-COO-
The rate of MET incorporation into rHSA was independent to the 
incubation period. Whereas, incorporation of glucose to rHSA was 
concentration depended. In cases of glucose binding, the incubation of 
glucose to rHSA was incorporation was linear and time dependent, 
whereas, glycosylation of rHSA was affected by MET in a concentration 
and time independent manner as shown in fig. 5 earlier. 
groups are 
“blocked” by internal-OH bonds. 
We had observed that MET inhibits non-enzymatic glcosylation of 
rHSA. Protein binding MET to albumin was low and concentration 
independent as depicted in fig. 6.  
Binding of MET to glycosylated HSA has followed the same pattern 
as that of non-glycosyalted HSA with significantly lower in binding of 
MET to glycated albumin. 
 
 
Fig. 6: Effect of pH on Non-enzymatic glucosylation of rHSA 
 
CONCLUSION 
Glycosylation of albumin may alter its binding properties. In Non-
Insulin Dependent Diabetes Mellitus patients MET treatment is 
generally used in high daily dose with a mean plasma concentration 
ranging from 1-5 µg/ml. MET has shown competitive inhibition of 
D–(+)-glucose binding to rHSA. The serum albumin may possess 
some cationic exchanger sites which exposed more at specific pH 
value. The organic cations are having higher inclination toward rHSA 
at that specific pH value in a concentration independent manner, 
which suggest that albumin may contain specific and limited number 
of cation exchange site. A liquid chromatography coupled to mass 
spectrometric method was developed and validated as per USFDA 
bioanalytical method validation guideline. MET is extensively used 
concomitantly with sulphonyl urea (high protein bound drug 
category) and results obtained from these suggested that the non-
enzymatic glycosylation of rHSA in diabetic patients complicates 
MET+drug interactions. 
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